Cantargia

Lund, Sweden

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

$13.2M raised

May 2026

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Cantargia raised?

Cantargia has raised $13.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.

Who are Cantargia's investors?

Cantargia's investors include Sunstone Life Science Ventures, Fenja Capital, Lubio Science.

Where is Cantargia headquartered?

Cantargia is headquartered in Lund, Sweden.

What does Cantargia do?

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

What stage is Cantargia at?

Cantargia is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 21, 2026.

MLA

"Cantargia — Funding & Investors." VCBacked, May 21, 2026, https://www.vcbacked.co/company/cantargia. Accessed July 3, 2026.

APA

VCBacked. (2026). Cantargia — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/cantargia

Wikipedia (cite web)

{{cite web |title=Cantargia — Funding & Investors |url=https://www.vcbacked.co/company/cantargia |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 21, 2026.